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Immunotherapy for skin malignancies has ushered in a new era for cancer treatments by
demonstrating unprecedented durable responses in the setting of metastatic Melanoma.
Consequently, checkpoint inhibitors are now the first-line treatment of metastatic
melanoma and widely used as adjuvant therapy for stage III disease. With the observation
that higher tumor mutational burden correlates with a better response, checkpoint
inhibitors are tested in other skin cancer types of known high tumor mutational burden
with promising results and recently became the first-ever FDA-approved treatment for
metastatic Merkel cell carcinoma. The emerging new standards-of-care will necessitate
more precise biomarkers and predictors for treatment response and immune-related
adverse events. Measurable immune-related mediators are currently under investigation
as factors that promote or block the response to cancer immunotherapy andmay provide
insights into the underlying immune response to the tumor. Cytokines and chemokines
are such mediators and are crucial for facilitating the recruitment and activation of
specific subsets of leukocytes within the microenvironment of skin cancers. The exact
mechanisms of how these meditators, both immunological and non-immunological,
operate in the tumor microenvironment is an area of active research, so to reliable
biomarkers of responses to cancer immunotherapy. Here, we will review and summarize
the expanding body of literature for immune-related biomarkers pertaining to Melanoma,
Basal cell carcinoma, Squamous cell carcinoma, and Merkel cell carcinoma, highlighting
clinically relevant checkpoint inhibitor therapy biomarker advancements.
Keywords: biomarkers, checkpoint inhibitors, cytokines, chemokines, melanoma, Squamous cell carcinoma,
Basal cell carcinoma, Merkel cell carcinoma
INTRODUCTION
In recent years, the field of cutaneous oncology has been invigorated by novel therapies that
modulate the immune system, and shifted away from conventional chemotherapy, radiation, and
targeted therapy. Immune checkpoint inhibitors (CPIs) are at the center of this new treatment
paradigm, providing unprecedented rates of response in Malignant Melanoma (MM), Basal cell
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carcinoma (BCC), Squamous cell carcinoma (SCC) and
metastatic Markel cell carcinoma (mMCC). The most impressive
clinical difference of immune-based therapies in comparison
with targeted therapy is the durability, while the majority of the
complete responder treated with CPIs still cancer free (>60%)
(1) vs. <30% at 4 years treated with dabrafenib plus trametinib,
a regimen for BRAF-mutated patients (2). However, despite
the promising results of CPI treatment in several cancers, only
a subset of patients show long-term response, and CPI-based
therapies can result in severe and potentially life-threating side
effects termed immune-related adverse events (irAEs). The
overall incidence rate of irAEs has been reported occur in up
to 90% of patients treated with anti-CTLA-4 (3) and 70% of
patients treated with PD-1 or PD-L1 antibodies (4, 5), with
serious toxicities (> grade 3) needing treatment discontinuation
for anti-PD-1 antibody therapy, anti-CTLA-4 antibody therapy,
and combination therapy at 21, 28, and 59%, respectively,
in large phase III trial analyses(6, 7). It is still unclear of the
mechanisms of irAEs and why some patients develop them, nor
why certain CPIs cause certain irAEs or their effect on patient
outcomes. Hence, predictive biomarkers that can aid in the
more precise delivery of immunotherapy to patients are urgently
needed. Thus, far, few biomarkers have been established that
can predict treatment success and positive clinical outcomes
for patients. Mutations in tumor cells are thought to be a
mechanistically relevant and an important initial event for
the generation of neoantigens that contribute to the initial
anti-tumor immune response (8–12). Tumor mutational burden
(TMB) became one of the first analytic tools to have a significant
correlation with response rate and prognostication (10, 11, 13).
Programmed death-ligand 1(PD-L1) is a transmembrane
protein, capable of being expressed by most tissues, that plays a
major role in suppressing the immune system via engagement
of programmed death protein 1 (PD-1) expressed on activated
T cells. The inflammatory cytokines produced following T cell
activation results in the expression of PD-L1 in the surrounding
tissue and promote selective immune tolerance. In the tumor
microenvironment, PD-L1 can be overexpressed by the tumor
cells and antigen-presenting cells (APCs), in turn blocking
the appropriate T cell immune responses required for tumor
rejection. PD-L1 expression is currently the only U.S. FDA
approved, commercially available predictive tool that helps
identify patients who are likely to benefit from therapy that
blocks the programmed death protein 1 (PD-1)/PD-L1 axis
pathway (14). Both biomarkers serve to estimate the statistical
likelihood of treatment success, but seldom are either used
in practice as the major clinical decision factor for which
to deploy CPIs for a patient, perhaps due to their relatively
low positive predictive value and undefined or sometimes
controversial correlation with overall survival (15, 16). As more
sophisticated means of patient immune monitoring, both on and
off therapy, are being developed, other potential biomarkers are
being investigated. In addition, it is worth noting that although a
number of reviews have addressed the importance of chemokines
and cytokines in skin cancer progression and metastasis (17–23),
fewer, if any, have addressed their potential as biomarkers for
treatment outcomes in skin malignances. Here, we offer a brief
overview of the current and emerging standard-of-care drugs
used in cancer immunotherapy for metastatic skin cancers, and
provide updates on immune-related biomarker advancements
pertaining to MM, BCC, SCC, and mMCC, including TMB,
PD-L1, novel immune activation/exhaustion markers, as well
as relevant cytokines/chemokines, highlighting research that
may be invaluable for the diagnostic, prognostic and predictive
information helpful in establishing better clinical outcome.
MECHANISM OF TUMOR IMMUNE
ESCAPE AND CLINICAL IMPACT OF
IMMUNE CHECKPOINTS IN METASTATIC
SKIN CANCER
CTLA-4 and PD-1 are both elements of a naturally evolved
network of peripheral tolerance responsible for maintaining
immune homeostasis and preventing overt autoimmunity. Early
studies in animal models showed that cancers exploit these
regulatory mechanisms, as checkpoint proteins are frequently
over expressed in the tumor microenvironment. CTLA-4 is
upregulated during T cell activation and eventually outcompetes
costimulatory molecule CD28 for CD86 and CD80 expressed on
antigen-presenting cells, halting further activation (24–26). CD86
and CD80 are known to be up-regulated at sites of inflammation
and are capable of being removed from the cell surface through
process known as trans-endocytosis by CTLA-4-expressing cells
as a method also of block CD28 co-stimulation (27). In addition,
CTLA-4 engagement enhances Treg suppressive function (28).
Anti-CTLA-4 antibodies are capable of blocking and preventing
this interaction, effectively shifting the balance back toward T
cell activation (3, 4, 29). Pre-clinical and clinical data show
CTLA-4 blockade results in the activation of both CD4 and
CD8 effector cells in favor of anti-tumor immunity. The effect
on the suppressive capacity of regulatory T cells in the tumor
microenvironment remains controversial and is an area of active
investigation (30–32). While the CTLA-4 pathway appears to
regulate anti-tumor immunity in the draining lymph nodes,
the PD-1/PD-L1 axis appear to take place in the local tumor
microenvironment (33–35), PD-1 is expressed highly on T cells
following repeated activation and chronic stimulation (36). As
opposed to the draining lymph nodes, the PD-1 ligands PD-L1
and PD-L2 are more widely expressed and upregulated at effector
sites of immune responses such as at inflamed tissues or the
tumor microenvironment itself where they function to suppress
T cell responses (36). The importance of interferon signaling
in regulating the expression of PD-L1 and PD-L2, suggests that
their expression patterns in advanced cancer and following CPI
treatment may reflect a mechanism of primary or acquired
resistance (34, 37). PD-1 and PD-L1 interaction inhibits T cell
proliferation, survival, and effector function including cytokine
release and tumor-targeted killing and can promote regulatory
T cells differentiation (36, 38–41). Blocking this interaction via
anti-PD-1 or anti-PD-L1 monoclonal antibodies restores the
T cell from its “exhausted” phenotype, improves local T cells
proliferation and effector function, and ultimately results in anti-
tumor immunity (34).
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The tumor microenvironment is a key location where
tumor cells and the host immune system interact. When a
cancer-associated antigen triggers an initial immune response,
a series of tumor microenvironment modifications occur and
impact the fate of antitumor immunity (42). The mutation-
derived neoantigens are presented by the patients’ major
histocompatibility complex (MHC) as “foreign” antigens,
recognized as such by the patients’ immune system. The priming
and activation of these cancer-reactive T cells is thought to occur
in draining lymph nodes, generating helper, and cytotoxic T cells
which traffic into the tumor, exert effector functions, and carry
with them the potential to reject the tumor (43–45). At this
phase, however, the pro-inflammatory environment generated
by the inciting immune response favors the upregulation of
reactive “shut-down” mechanisms that function to restore
immune homeostasis, likely evolved to prevent aberrant immune
reactions and the destruction of healthy host cells Figure 1.
These checkpoint and tolerance mechanisms often prevent
successful tumor eradication, but their presence and detection
in the tumor microenvironment also provide evidence that
an initial immune recognition has occurred and a battle
between immune cells and tumor has begun. This is the
scenario in which immunotherapy can help offset the balance
toward tumor killing. This principle is behind the development
of PD-L1 testing as a companion predictive biomarker for
PD-1/PD-L1 based CPI treatment and is currently the only
commercially available FDA approved predictive biomarker for
cancer immunotherapy (section Tumor mutational burden, PD-
L1, and other tumor microenvironment-associated biomarkers
for checkpoint inhibitor treatment; Table 1). PD-L1 expression
in pre-treatment tumor or immune cells is upregulated as a
consequence of proinflammatory cytokine interferon-gamma
(IFN-γ ) released from T cells activation, presumably by
tumor-associated antigens within the microenvironment (44).
The presence of this immune response is correlated with a
significantly higher chance that PD-1 based treatment will work
in metastatic melanoma and a variety of other tumor types
(46, 47).
For metastatic skin malignancies, the durable response
rates from checkpoint blockade are unprecedented, with PD-
1 inhibitor monotherapy approaching 40% and the hallmark
combination approach of dual CTLA-4 and PD-1 blockade
providing objective responses approaching 60% in patients
with metastatic melanoma, a cohort with a historically dismal
treatment response rate and prognosis (48). Furthermore, of the
patients that achieve a complete response, >90% remain disease
free even with monotherapy, with patients from the largest
KEYNOTE-01 (NCT01295827) study still not reaching median
treatment response duration at 5 years (49). Encouragingly, the
response rates in non-melanoma skin cancers follow a similar
trend, with avelamub (anti-PD-L1 antibody) now approved as
first-line therapy for metastatic MCC, and cemiplimab (anti-
PD-1 antibody) granted FDA priority review in 2018 for SCC,
with clinical trials are underway for BCC (NCT03132636,
NCT02690948). Despite these advancements, the observation
that durable objective response can occur in these difficult to
treat metastatic solid tumors with the blockade of checkpoint
pathways comes with the frustration that treatment responses
and their associated irAEs are highly variable and unpredictable.
Nevertheless, there are several irAES with reported correlations
to clinical response, notable examples include autoimmune
skin depigmentation (vitiligo) and Type 1 Diabetes (8, 50–
59). The precise mechanism of irAEs, whether they are driven
solely by the reduction of T cell exhaustion and aberrant
activation to autoantigens via CPI treatments or by changes in
the epigenetic transcriptional control in the effector T cells, is
currently unknown (52). As detailed below, research efforts are
rapidly underway to help uncover the determinants of anti-tumor
response for immunotherapy and their associated predictive
biomarkers.
OVERVIEW OF CURRENT AND EMERGING
STANDARD-OF-CARE TREATMENTS IN
METASTATIC SKIN CANCERS
Metastatic melanoma is associated with the greatest mortality
of all the skin malignancies and is often considered one of the
deadliest metastatic cancers. Prior to the US FDA approval of
the CPI ipilimumab in 2011, even with multi-modality systemic
therapy, including surgery, radiation, and chemotherapy, the
prognosis was grim, with an estimated 5-year survival of <20%
and median survival of <1 year (60, 61). Fortunately, the
standard-of-care has been shifting over the last decade, as a direct
consequence of the success of CPIs. Drugs that block the PD-
1 pathway (nivolumab, pembrolizumab, etc.) have been shown
to provide higher response rates with a comparable durability
of response and less toxicity than the cytotoxic T-lymphocyte
associated protein 4 (CTLA-4) blocker ipilimumab (49, 62–64).
Consequently, PD-1 blocking CPIs, with or without CTLA-4
blockade (ipilimumab) are now the preferred US FDA approved
first-line therapy (Table 2). Chemotherapy, surgery, radiation,
MEK inhibitors, and BRAF-mutation targeted therapy rarely
produce durable responses, as mentioned above (2). They are
options reserved for cases where rapid debulking and early
response is necessary, often due to cancer impingement on
vital structures (i.e., large brain metastasis), as they are able
to achieve a faster, albeit often temporary, regression of large
masses (NCCN guidelines version 3.2018). Older generation
immunotherapy drugs such as systemic high-dose interleukin-
2 (IL-2) or interferon alpha (IFNα) and bio-chemotherapy
combinations (decarbonize, cisplatin, vinblastine, IL-2, and
IFNα) are rarely recommended due to low efficacy and high
toxicity, even in the adjuvant or second-line settings. While we
await updated metastatic melanoma survival data in the age
of modern immunotherapy, CPIs are expected to significantly
improve and thus transform the standard-of-care and outlook for
patients with this devastating cancer.
BCC, SCC, and mMCC comprise the vast majority of non-
melanoma skin cancers. Like melanoma, at the early stage,
local and surgical therapies are often curative and systemic
therapies are only considered in settings where the tumor is
unresectable or has metastasized. When disseminated, these
cancers are comparable in mortality to metastatic melanoma
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FIGURE 1 | The “Physics” of Cancer Immune Response. (0) The steady state of the immune system at homeostasis is without effector cell activation and
inflammation. (1) At its inception, a cancer cell may be invisible to the immune system and not trigger any response. (2) As cancer cells gain mutations over time,
protein products foreign to the host are formed and these neoantigens increasingly gain recognition by the immune system. (3) “Potential energy” increases for the
immune system to act, and reaches a threshold maximum where an immune attack on the cancer cells begins. (4) Naturally evolved feedback mechanisms such as
Tregs, CTLA-4, and PD-1 attempt to restore the immune system back to homeostasis and halts ongoing immune response, however, unlike infectious elements that
have been cleared, the immune suppression is often premature as antigens generated from cancer cells persist with the growing tumor. This is the point of intervention
where agents such as checkpoint inhibitors are thought to exert its effect. (5) After successful blockade of immune checkpoints, the “kinetic energy” of the immune
system resumes and can reach its maximum and tumor can be fully eradicated.
TABLE 1 | Commercially available PD-L1 diagnostic tests.
IHC assay Assay developer Companion drug FDA indications Expression source *Scoring cutoff Antibody clone
Ventana
PD-L1 (SP142)
Ventana Atezolizumab
(anti-PD-L1)
Bladder Cancer,
NSCLC
FFPE of tumor
infiltrating immune cells
and tumor cells
≥10% Rabbit SP142
Ventana
PD-L1
(SP263)
Ventana Durvalumab
(anti-PD-L1)
Bladder Cancer FFPE of tumor cells ≥25% Rabbit SP263
PD-L1
IHC 22C3 pharmDx
Dako Pembrolizumab
(anti-PD1)
NSCLC, Gastric
Adenocarcinoma,
Cervical Cancer
FFPE of tumor cells
and stroma
≥ 1% Mouse 22C3
PD-L1
IHC 28-8
pharmDx
Dako Nivolumab
(anti-PD1)
NSCLC, Melanoma,
SCC of Head and
Neck, Bladder Cancer
FFPE of tumor cells ≥ 1% Rabbit 28-8
*Scoring cutoff varies by indication/study; unless otherwise indicated, reference value provided is based on sample non-small-cell lung cancer tumor cell IHC cutoffs.
and are notoriously difficult to treat. Similarly, the paradigm
for their systemic treatment has shifted away from conventional
cytotoxic modalities, which are often ineffective, to CPIs. In 2017,
the FDA accelerated approval avelumab, a PD-L1 blocker, as
the first-ever and only FDA approved drug for the aggressive
metastatic MCC highlighting this trend (Table 2). For metastatic
BCC and SCC, currently approved targeted therapies such as
hedgehog pathway inhibitors vismodegib and sonidegib for
BCC and epidermal growth factor receptor pathway inhibitors
(cetuxmimab, pantimumumab, gefitinib, erlotinib) for SCC,
although with proven response rates, face the challenge primary
or acquired resistance in their respective pathways and have
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TABLE 2 | Current status of immunotherapy drugs in metastatic skin cancer.
Cancer type Pre-immunotherapy drugs Immunotherapy drugs US FDA approved
Metastatic Melanoma Chemotherapy (i.e., Dacarbazine, Temozolomide,
nab-Paclitaxel, Carboplatin); Targeted therapy (i.e.,
Dabrafenib, Trametinib, Combimetinib, Vemurafenib,
Binimetinib)
High-dose Interleukin-2, Interferon-α (adjuvant only),
Ipilimumab (anti-CTLA-4), Nivolumab (anti-PD1),
Pembrolizumab (anti-PD1), Talimogene
Laherparevec (oncolytic virus)
All Approved
Merkel Cell Carcinoma Chemotherapy (i.e., Carboplatin, Etoposide,
Cyclophosphamide, Doxorubicin, Vincristine);
Targeted therapy (i.e., Pazopanib)
Avelumab (anti-PD-L1), Pembrolizumab, Nivolumab,
Ipilimumab, Talimogene Laherparevec
Avelumab (approved), Others (in
clinical trial)
Squamous Cell
Carcinoma
Chemotherapy (i.e., Cisplatin, Doxorubicin,
Bleomycin, Fluorouracil); Targeted therapy (i.e.,
Cetuximab, Panitumumab)
Cemiplimab (anti-PD1), Nivolumab, Pembrolizumab,
Talimogene Laherparevec
Cemiplimab (under FDA priority
review), Others (in clinical trial)
Basal Cell Carcinoma Chemotherapy (i.e., Cisplatin, Doxorubicin,
Paclitaxel); Targeted therapy (i.e., Sonidegib,
Vismodegib)
Ipilimumab, Nivolumab, Pembrolizumab,
Talimogene Laherparevec
All in clinical trial
response durations that are often short-lived (65–69). Due to
their shared feature of high tumor mutational burden (70–
72), PD-1 blockade has demonstrated significant numbers
of durable responses for SCC and BCC (73–76) and may
likely be considered as a new standard-of-care for these
indications.
As the standard-of-care for these different types of metastatic
skin cancers converge on CPIs, the treatment decision process
of BCC, SCC, and MCCs will likely share the clinical experience
gained from MM. Some major challenges remain in the clinical
deployment of CPIs for metastatic skin cancers: (1) The response
rate for PD-1 inhibitor monotherapy tops out at around 40%, and
while in a recent phase 3 trial combination therapy with PD-1
and CTLA-4 blockade found the response rate closer to 60%, it
carries a significantly more serious toxicity profile leading to the
frequent need for early treatment discontinuation (6, 48, 63, 77).
(2) The general unpredictability of responses/toxicities of CPIs
makes monitoring challenging and the determinants on how
to shift the balance toward more response and less toxicity are
largely unknown. (3) What happens if there is a relapse? Are you
able to re-start CPI treatment again and get a response? Does
resistance to one CPI treatment pathway infer resistance to all?
(4) When to stop treatment? The high cost associated with CPIs
makes it challenging to continue treatment indefinitely (78), and
despite some reports of prolonged efficacy after discontinuation,
the optimal time to stop treatment to ensure sustained complete
response is currently unknown (49). In practice, in responding
patients, many clinicians continue treatment until complete
response plus at minimum 1 year after, but there have been
no randomized clinical trials designed to address this important
question. These and other considerations necessitate the interest
and resources dedicated to better the mechanistic understanding
of how CPIs work as well as develop biomarkers for treatment
so that we can more rationally and efficiently deploy them.
Ideally, we can improve upon current overall response to CPIs
while lessening toxicity, but until then, predictive biomarkers
could help target PD-1 monotherapy to those who have a
higher probability of response and help identify those for
whom a more aggressive combination of immunotherapy is
needed.
TUMOR MUTATIONAL BURDEN, PD-L1,
AND OTHER TUMOR
MICROENVIRONMENT-ASSOCIATED
BIOMARKERS FOR CHECKPOINT
INHIBITOR TREATMENT
TMB is a mechanistically rational biomarker for CPI treatment
efficacy. As the skin is the first line of host defense against
environmental assaults, providing the physical barrier against the
mutagenic effects of UV radiation, invasion of viral pathogens,
and colonization of commensal bacteria, it stands to reason
that this organ system and cancers that arise from it should
accumulate higher antigenic mutational burden for T cell
detection (79, 80). Indeed, all metastatic skin cancers have
demonstrated significant responses to CPI treatment (9), and
TMB analysis has shown that melanoma, SCC, BCC, and MCC,
typically harbor mutational and antigenic loads at the higher
end of the mutational spectrum (8, 9, 70–72). Over time, the
environmental assaults on the skin accumulate mutations and
result in a “tug-of-war” between oncogenic driver mutations that
create cancerous lesions and immunogenic passenger mutations
that may then cause its regression from immune recognition (81–
83). In theory, high tumor mutational burden provides a source
of tumor-associated peptides that become neoantigens which
trigger the initial differential T cell recognition of cancer cells
from normal cells and provide the requisite anti-tumor immune
response that allows patients to respond to immune- based
treatments (79, 84). Clinical evidence is supportive for TMB as
a biomarker of checkpoint response, as there is a correlation with
the number of mutations and the chance such a mutation will
provide a productive immunogenic antigen. In addition, clinical
observations correlating cancers with high tumor mutational
load with a better checkpoint blockade response raised the initial
possibility of an association (10, 11). This hypothesis was further
validated after reports that DNA mismatch-repair deficiency
associated cancers (microsatellite instability-high) harbor some
of the highest known tumor mutational burdens. Patients with
this class of tumors have one of the highest response rates to PD-1
inhibitors (85, 86). These findings eventually led to accelerated
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FDA approval in 2017 for all cancers that are microsatellite
instability-high.
PD-L1 is currently a U.S. FDA approved biomarker for PD-1
based CPI therapies. In general, patients with higher PD-L1 levels
by immunohistochemistry have higher chances of responding
to PD-1 based CPI therapy (87, 88). However, the predictive
value for response is more accurate for patients with lung cancer
than for skin cancers such as melanoma (89, 90), as durable
responses to PD-1 CPI treatment has been observed in some
melanoma patients with low expression of PD-L1. In terms of
correlation to overall survival, interestingly, the majority of prior
reports (before the wide usage of immunotherapy) suggest that
high expression of PD-L1 correlates with shorter survival, even
in settings of a high tumor mutational burden (16, 91–94). The
paradoxical relationship between lower historical overall survival
and higher PD-1 therapy response rate can be reconciled with
the explanation that tumors with high tumor mutational burden
generally leads to higher local expression of PD-L1, because
more T cells sensitive to the tumor are likely to be present
to be activated. On the other hand, highly mutated tumors
would also have a higher potential to evolve driver mutations or
pathways for adaptive resistance (81, 95–97) (Figure 1), therefore
bypassing mechanisms of tumor rejection. Thus, while the value
of PD-L1 as a biomarker for predicting better PD-1 therapy
response is established, its use as a predictor for overall survival
remains controversial and is to be determined in the era of
immunotherapy. Neither the use of TMB nor PD-L1 is perfect,
and the use of the combination of TMB and PD-L1 to identify
likely responders to CPIs may be costly. Until more effective
biomarkers are available, one clinical strategy for their use in skin
cancers that has demonstrated some success is to utilize TMB
and PD-L1 together as negative instead of positive predictors
of response- when a low TMB and PD-L1 immune signature is
present, this indicates that stronger immunotherapy such as PD-1
and CTLA-4 combination therapy should be utilized (98).
As more sophisticated means of patient immune monitoring
both on and off therapy are being developed, other potential
biomarkers are being investigated. For example, various other
T cell activation and exhaustion markers including inducible
T cell costimulatory (ICOS), 4-1BB (CD137), PD-1, CTLA-4,
lymphocyte activation gene 3 (LAG-3), T cell immunoglobulin
mucin-3 (Tim-3) and CD39, whether in circulation or within
the tumor microenvironment, are now being correlated with
response rates (46, 99–104) These, and other immune activation
related biomarkers are biological surrogate markers that
collectively signify an active immune response within the
tumor microenvironment for which drugs such as CPIs can
potentially take advantage, and may add to the predictive
value and reliability of tumor mutational burden and PD-
L1 expression (Figure 1). For biomarkers that are not directly
associated with immune activation, serum lactate dehydrogenase
level assessments have traditionally been made in the clinic
as a surrogate indicator of disease progression and poor
prognosis in melanoma, based on the rationale that lactate
dehydrogenase is released upon cell damage and death associated
with elevated tumor burden. Low baseline levels further
demonstrate a favorable response correlation with CPI usage
(105). Additionally, several novel non-immune activation related
biomarkers of CPI response have been proposed, and include
total tumor volume (101, 106), the presence of liver metastasis
(98, 107), MHC protein expression (108), and the composition
of the gut microbiome (109–112). Total tumor volume and liver
metastasis assessment offer the benefit of cost-effectiveness and
easier accessibility in clinical use, as they can be readily identified
with standard-of-care imaging. Both high tumor volume and
liver metastasis have independently been reported to result in
unfavorable alterations in systemic T cell profiles (98, 101),
suggesting yet-to-be discovered mechanisms of tumor immune
regulation. Gut microbiota composition of certain bacterial
strains and overall microbiome diversity appear to correlate
with response rates (110–112), but larger and more geographical
and demographically diverse studies are likely needed before
conclusions can be finalized to influence clinical practice.
Finally, the accumulation of the variety of rationally developed
biomarkers may eventually contribute to patient-individualized
“immunoscoringm,” a promising precision-medicine strategy
that may be immunotherapy-focused and disease-agnostic,
and effectively allow for constant updates and dynamic
improvements in the fast-paced predictive biomarker field (113).
CYTOKINES AND CHEMOKINES AS
PROGNOSTIC INDICATORS FOR SKIN
CANCER
Cytokines and chemokines influence a complex network of
regulation regarding immune cell function and trafficking.
They can be divided readily into pro-inflammatory, anti-
inflammatory, mitogenic, and chemotactic subgroups and are
capable of contributing to particular functions dependent
on their microenvironment. In addition to these properties,
cytokines and chemokines and their receptors play a part in
biological functions relevant to oncogenesis, including tumor
cell proliferation, protease induction, and angiogenesis. Thus,
cytokines and chemokines can facilitate immune-mediated
tumor rejection or promote tumor progression as well as
metastasis. These dichotomous associations and their underlying
mechanism have become an area of active research not only
for biomarker development but also for novel therapeutic
targeting. Assessment of cytokine and chemokine profiles within
the tumor microenvironment or in circulation, may greatly
increase the resolution of our understanding of the status of the
immune response to the tumor. The ability to tease apart the
delicate balance of effector vs. regulatory elements in the tumor
microenvironment will be essential to patient therapeutic design
targeting a variety of critical aspects of the immune axis that
could be dysregulated in cancer disease progression.
A number of chemokines and cytokines have been
investigated for their roles in skin malignancies. Pro-
inflammatory cytokines including TNF-α, Interleukin-16
(IL-16), IL-17, IL-21, IL-22, and IL-23 have all been associated
with tumorigenesis and an inflammatory environment.
Cytokines like IFN-γ and IL-12 are cytotoxic T cell related
cytokines associated withmounting a cytolytic immune response.
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Their anti-tumor response is well-characterized in limiting skin
cancer development (114–117). Immune-modulating cytokines
including IL-10 and TGF-β are reported to oppose anti-tumor
response since they are made predominantly by T regulatory cells
to suppress cytotoxic responses against the skin malignancies
(114, 118–120). However, like all cytokines, their roles are
context-specific. For example despite circulating IL-10 levels
have been associated with poor patient prognosis in a number of
cancer settings, yet IL-10 expressing CD8T cells confer a positive
prognosis in patients with lung cancer (121–123). Chemokines,
similarly, have long been associated with the recruitment of
cells into the skin and can be sub-grouped as homeostatic or
pro-inflammatory chemokines. Homeostatic chemokines are
expressed constitutively and play key roles in normal leukocyte
development and trafficking, pro-inflammatory chemokines are
inducible and are responsible for trafficking to inflammation
associated events (124). The chemokine receptor CXCR3 is
expressed on inflammatory infiltrates and mediates attraction
to the IFN-γ -inducible chemokines CXCL9 (or MIG), CXCL10
(or IP-10), and CXCL11(I-TAC) into the skin (125–129).
These pathways of recruitment are also capable of regulating
immune cell differentiation and activation, favoring Th1 and
IFN-γ -production, respectively. The IFN-γ /CXCL9, CXCL-10,
CXCL-11/CXCR3 axis can be a double-edged sword in cancer,
promoting an anti-tumor effect but also increasing the capability
of cancer cell proliferation, angiogenesis and metastasis (125).
CXCL1 (melanoma growth-stimulatory activity/growth-
regulatory protein α) and CXCL8 (IL-8) have important roles
in inflammation, angiogenesis, tumorigenesis, and wound
healing (130). However, these pathways can also be hijacked in
cancer, promoting inflammation, inducing angiogenesis, tumor
growth, and metastasis (131). For melanoma the expression of
chemokine receptors CCR10, CXCR4, and CCR7 have been
attributed to tumor escape and preference for metastasis (132). A
number of reviews have addressed the importance of chemokines
in skin cancer growth and metastasis (17–22, 133). Fewer, if any,
have addressed their potential as biomarkers for prognosis or
treatment outcomes.
CYTOKINES AND CHEMOKINES AS
BIOMARKERS FOR CHECKPOINT
INHIBITOR TREATMENT IN MALIGNANT
SKIN CANCERS
Although limited, a number of groups that have studied cytokines
and chemokines as biomarkers for predicting clinical outcomes
to CPI therapies for skin malignancies. The prototypical T cell
growth factor, IL-2, and the major anti-inflammatory cytokine,
IL-10, have yielded surprisingly little correlation with actual
clinical response rates, possibly due to the transient and locally
expressed nature of these cytokines (88, 134). Available research,
with many focused on patients treated with CTLA-4 inhibitors
that were approved much earlier, with their main findings and
predicted clinical outcomes are summarized in Table 3 and
discussed below.
TGF-β and IFN-γ
Tarhini et al. (135) evaluated circulating serum levels of
cytokines, chemokines and a number of growth factors in
response to CTLA-4 therapy (ipilimumab) finding a strong
correlation between baseline levels of IL-17 and irAEs, and
the combination of TGF-β and IL-10 baseline levels were
predictive of relapse against therapy (135). Interesting, TGF-β
has also been proposed as a serum marker of response to PD-1
(nivolumab) therapy in a cohort of MM patients by Nonomura
et al. (120), with significantly increased pre-treatment levels,
but not post-treatment levels, reported between responders
and non-responders (120). The group found increased levels
of newly characterized CD4 population, Th9 cells, that are
generated in the presence of TGF-β and IL-4, suggesting that the
blockade of PD-1/PD-L1 axis promoted Th9 cell differentiation,
which in turn suppressed melanoma progression and increases
cytotoxic activities of CD8T cells (120). Although conflicting,
the presence of TGF-β is reflective of a reduced immune
response and therefore more likely to represent resistance to
CPI treatments (152–154). In melanoma TGF-β production is
positively correlated relative to disease progression, acting as
a tumor promoter rather than a suppressor, and negatively
regulating the activity of T cells by blocking IL-2 production
(119).
The importance of an immune-active tumor
microenvironment in clinical responses for CPI treatment
has been shown in a number of melanoma patient cohorts. Early
work performed Herbst et al. (140) to understanding predictive
correlates of response to PD-1 therapy (MPD3280A) examined
blood-based biomarkers. However, despite increases in IL-18,
CXCL11 (ITAC), and IFN-γ found during the initial stages
of treatment, there was no correlation to patients’ long-term
response and outcomes (140). Examining tumor tissue gene
expression, however, they did find a number of genes associated
with enhanced T-effector cell activity in pre-treatment responsive
tumors compared to non-responsive tumors, including IFN-γ ,
IDO-1, and CXCL9 (140). In 2012, Ji et al. reported a phase II
clinical trial in which 45 melanoma patients were treated with
CTLA-4 (ipilimumab), and treatment was found to induce IFN-
γ -inducible genes IDO1, GBP1, and class II MHC molecules and
a number of Th1-associated marker genes IFN-γ , CCL4, CCL5,
CXCL9, CXCL10, andCXCL11 in patients with a clinical response
(141). The importance of IFN-γ gene signatures for response
has been published similarly by Ribas et al. (146) in a test cohort
of 19 melanoma patients treated with PD-1. Comparing the
gene signature of responders vs. non-responders revealed a
number of top-ranking genes that were strongly associated
with IFN-γ signaling and correlation with IFN-γ expression.
Their preliminary IFN-γ gene signature included IFNG, STAT1,
CCR5, CXCL9, CXCL10, CXCL11, IDO1, PRF1, GZMA, and
MHCII HLA-DRA and an expanded immune signature of genes
related to cytolytic activity (e.g., granzyme A/B/K and PRF1),
cytokines and chemokines (e.g., CXCR6, CXCL9, CCL5, and
CCR5), T cell markers (e.g., CD3D, CD3E, CD2, IL2RG), NK
cell activity (e.g., NKG &, HLA-E), antigen presentation (e.g.,
CIITA, HLA-DRA) and other immunomodulatory factors (e.g.,
LAG3, IDO1, and SLAMF6) were able to differentiate between
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TABLE 3 | Chemokine & Cytokine biomarkers investigated for CPI treatment outcomes.
Treatment Biomarker
category
Biomarker Associated outcome Study summary References
MELANOMA
CTLA-4 Blood soluble
immune factor
IL-17, TGF-β & IL-10 Baseline levels predict
toxicity and relapse
33 patients; blood and
serum; baseline and 6
weeks following treatment
(135)
CTLA-4 Blood soluble
immune factor
IL-6 High levels above media
associated with treatment
failure
40 patients; blood and
serum taken at baseline and
following up to 4 treatments
(136)
CTLA-4 Blood soluble
immune factor
CXCL11 & sMICA High baseline levels
associated with poor overall
survival to treatment
137 patients; blood and
serum; independently
validated in different cohort;
baseline levels
(137)
CTLA-4 Blood soluble
immune factor
IL-8 Decreases in serum levels in
responders vs. increased
levels in non-responders
8 patients; blood and
serum; same response
correlated with iBRAF
treatment responses
(138)
PD-1 Blood soluble
immune factor
IL-8 Early changes (decrease)
were strongly associated
with response
29 patients; blood and
serum; independently
validated in cohort of 12
melanoma and 19 NSLCL
patients
(139)
PD-1 Blood soluble
immune factor
IFN- γ , IL-6 & IL-10 Higher baseline levels were
found in patients with
objective tumor response
compared to those with
progression
37 patient; blood and
serum; baseline and day 43
(134)
PD-1 Blood soluble
immune factor
IL-9 & TGF-β Increase frequency of IL-9
producing CD4T cells and
increased pre-treatment
TGF-β serum levels in
responders
46 patients; 18 responders
and 28 non-responders; pre
and post treatment (3
infusions)
(120)
PD-1 Blood soluble
immune factor and
Tumor tissue gene
expression
IFN- γ , IL-18, CXCL11
& IL-6
Serum changes were
observed. Increased IFN- γ
genes in pretreatment tumor
biopsies associated with
response
Blood and serum samples
taken before and after
treatments
(140)
CTLA-4 Tumor tissue gene
expression
IFN-γ , CCL4, CCL5,
CXCL9, CXCL10,
CXCL11, IDO1, GBP1
and class II MHC
molecules
Higher baseline levels of
immune-related genes
predicted clinical response
45 patients; tumor biopsy;
pre and post treatment
(141)
CTLA-4 Tumor
Whole-exome
sequencing
IFNGR1, IFNGR2,
JAK2, IRF1, IFIT1,
IFIT2, MTAP, miR3,
SOCA1 & PIAS4
Tumors that are resistant to
treatment contain genomic
defects in the IFN- γ
pathway genes
12 non-responders and 4
responders; Tumor samples
(142)
CTLA-4
followed by
PD-1
Tumor tissue gene
expression
GZMA, GZMB, PRF1,
HLA-DQA1,
HLA.DRB1, IFNG,
STAT1, CCL5,
CXCL9,−10, - 11,
ICAM1-5 & VCAM-1
Active immune signature in
early tumor samples were
highly predictive of response
5 responding patients and 6
non-responders following
PD-1 treatment; tumor
samples
(143)
PD-1 Tumor Whole
exome sequencing
JAK1 & JAK2 Tumors that are resistant to
treatment contain genomic
defects in the IFN- γ
pathway genes
4 patients; initially had an
objective response to
treatments but went on to
have disease progression
(144)
PD-1 Tumor tissue gene
expression
IFNG, STAT1, CCR5,
CXCL9, CXCL10,
CXCL11, IDO1, PRF1,
GZMA, MHCII
HLA-DRA, CXCR6,
Immune-related signature
using RNA from baseline
tumor samples which
correlated with clinical
benefit
19 patients; tumor biopsies
prior to treatment; validated
in 62 melanoma patients
(145–147)
(Continued)
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TABLE 3 | Continued
Treatment Biomarker
category
Biomarker Associated outcome Study summary References
TIGIT, CD27, CD274
(PD-L1), PDCD1LG2
(PD-L2), LAG3, NKG 7,
PSMB10, CMKLR1,
CD8A, IDO1, CCL5,
CXCL9, HLA.DQA1,
CD276, HLA.DRB1,
STAT1 & HLA.E
PD-1 Tumor tissue gene
expression
CD3D, CD3E, CD3G,
CD247, ZAP70, CD2,
CD28, ICOS, IL12Rb1,
CXCR3, STAT4, PRF1,
IFNG, CD8A, CD8B,
GZMM & FLTSLG
Immune-related signature
from baseline tumor
samples where associated
with non-progressive
disease and progression
free survival
25 patients; tumor biopsies
prior to treatment
(148)
PD-1 Tumor tissue gene
expression
IFNG, IDO1, CXCL9,
CXCL10 & CXCL11
Strong positive correlation
between IFN-γ and
IFN-inducible genes is
associated with response
and prolonged overall
survival
21 melanoma patients;
tumor biopsies prior to
treatment; 17 NSCLC
patients
(149)
SCC
PD-1 Tumor tissue gene
expression
CXCL9, CXCL10,
IDO1, IFNG, HLA-DRA
& STAT1
IFN- γ signature may be
associated with clinical
response
56 patients; tumor RNA
extracted from FFPE slides
(150, 151)
PD-1 Tumor tissue gene
expression
CXCR6, TIGIT, CD27,
CD274 (PD-L1),
PDCD1LG2 (PD-L2),
LAG3, NKG 7,
PSMB10, CMKLR1,
CD8A, IDO1, CCL5,
CXCL9, HLA.DQA1,
CD276, HLA.DRB1,
STAT1 & HLA.E
Immune-related signature
using RNA from baseline
tumor samples which
correlated with clinical
benefit
Validated in 43 HNSCC
patients.
(145)
PD-1 Tumor tissue gene
expression
CD3D, CD3E, CD3G,
CD247, ZAP70, CD2,
CD28, ICOS, IL12Rb1,
CXCR3, STAT4, PRF1,
IFNG, CD8A, CD8B,
GZMM & FLTSLG
Immune-related signature
using RNA from baseline
tumor samples where
associated with
non-progressive disease
and progression free survival
5 patients; tumor biopsies
prior to treatment
(148)
HNSCC, Head and Neck SCC; NSCLC, Non-small cell lung cancer; FFPE, Formalin-Fixed Paraffin-Embedded
objective responses and non-responders. Additionally, the group
was able to further refine their IFN-γ and expanded immune
gene signatures within another cohort of 62 melanoma patients
(145–147), in which the baseline immune-related tumor samples
correlated with clinical benefit from treatment. The importance
of activated Th1 and cytotoxic T cells in mediating CPI mediated
tumor responses irrespective of the tissue environment was
also used to test and further refine the gene signature, with
the group finding these signatures capable of associating
with treatment response to pembrolizumab in HNSCC and
gastric cancer. Furthermore, the final T cell-inflamed gene
expression profile consisting of 18 genes, (CXCR6, TIGIT,
CD27, CD274 (PD-L1), PDCD1LG2 (PD-L2), LAG3, NKG 7,
PSMB10, CMKLR1, CD8A, IDO1, CCL5, CXCL9, HLA.DQA1,
CD276, HLA.DRB1, STAT1, and HLA.E), was tested against 9
tumor types (KEYNOTE-012; bladder, gastric, HNSCC, and
triple-negative breast cancer, KEYNOTE-028; anal canal, biliary,
colorectal, esophageal, and ovarian cancer) with most of the
gene signature positive association with response. The data
present by Ayers et al. (145) highlights the importance of the
T cell-inflamed microenvironment common to patients who
respond to anti-PD-1 CPI treatment regardless of the tumor type
or tissue type and also proposes a difference between resistance
mechanisms between non-responding patients that lack T cell
inflammation and those who have infiltration but lack clinical
response (145).
Chen et al. (143) followed a unique set of melanoma
patients that were initially treated with CTLA-4 followed by
PD-1 at progression, identifying a unique immune signature in
responders not evident in non-responding patients significant
after 2 to 3 cycles of treatment (143). Within the 411 significantly
differentially expressed genes of responders where a number of
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cytolytic makers (i.e., GZMA, GZMB, and PRF1), HLAmolecules
(e.g., HLA-DQA1HLA.DRB1) IFN-γ pathway genes (e.g., IFNG,
STAT1), chemokines (e.g., CCL5, CXCL9,−10, and 11) and select
adhesion molecules (i.e., ICAM1-5 and VCAM-1). The dataset
also allow for the comparison of pretreatment samples and after
treatment fold changes clearly differentiating responders from
non-responders, regardless of the pretreatment with CTLA-4.
These finding clearly support the assessment of early immune
responses can be highly predictive of overall response to therapy.
However, it should also be noted that these on treatment changes
maybe associated solely with treatment and not associated with a
mechanism of response. In additional Chen et al. also highlight
an angiogenic phenotype in non-responding patients (decreased
VEGFA), downregulation of antigen processing and presentation
(HLA genes) and defects in the interferon signaling pathways, all
of which are consistent with a number of previously published
works (142, 143, 155–159).
Prat et al. (148) evaluated pre- and post-PD-1
(pembrolizumab or nivolumab) treated tumor samples from a
range of cancers, including melanoma patients. Twenty three
immune related genes or signatures where identified to be
associated with non-progressive disease and progression free
survival, these included genes associated with the formation
of the TCR complex (e.g., CD3D, CD3E, CD3G, CD247, and
ZAP70), co-stimulatory factors (e.g., CD2, CD28, and ICOS)
and genes involved in differentiation (e.g., IL12Rb1, CXCR3,
and STAT4). In addition to apoptosis pathway genes involving
granzyme A, B and perforin 1, T cell receptor signaling (e.g.,
CD8A, CD8B, and IFN-γ ), cell adhesion molecules (e.g., CD4,
CD86, and integrinβ2), a number of toll-like receptors (TLR1,4,
7, and 8) and checkpoint molecules PD-1, PDL-2, and LAG3.
These signatures were found across all the different cancer types
assessed and 12 signatures tracking immune cells including
CD8T cell associated genes PRF1, CD8A, CD8B, GZMM,
FLTSLG, CD4T cell activated genes IL26 and IL17A as well
as NK cell and B cell genes and PDL-1, PD1, and CTLA4 and
IFN-signaling pathway activation (148). These findings are in
support of the Ribbas et al. (146), Ayer et al. (147), and Ayer
et al. (145) T cell and IFN activation predicting response to the
PD-1/PD-L1 treatment across multiple tumor types and tumors
with strong pre-treatment immunity.
Gao et al. (142) used whole-exome sequencing of tumor
tissues to show that tumors that are non-responsive to CTLA-
4 (ipilimumab) therapy have defects in IFN-γ pathway via
significantly higher somatic mutations including copy-number
variations and single-nucleotide variants in IFN-γ signaling
genes including IFNGR1, IFNGR2, JAK2, IRF1, IFIT1, IFIT2,
MTAP, and miR31 and amplification of IFN-γ suppressor genes
(SOCA1 and PIAS4) compared to responders (142). Similarly,
Zaretsky et al. (144) published a similar finding in melanoma
patients treated with anti-PD-1 antibody (Pembrolizumab)
finding that loss of function mutations within the IFN receptor
associated Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2) lead
to lack of response to IFN-γ leading to acquired resistance
to PD-1 blockade (144). However, both cohorts of patients
were small, 16 and 4, respectively, and require validation in
larger cohorts of patients and treatments. Similar observations
have been previously published by Tumeh et al. (45) in a MM
patient cohort treated with anti-PD-1 (pembrolizumab), with
baseline and post-dosing biopsies for phospho-STAT1 (pSTAT1),
an immediate downstream effector upon IFN-γ binding (45).
Proposing that the PD-L1 tumor expression can be linked to
interferon production within the tumor microenvironment via
T-cell recognition, patients that were found to have a response
to therapy had significantly higher expression of pSTAT1 at
baseline and during treatment compared to progression group
(45). Highlighting again the importance of a pre-existing tumor
immune response in patient outcomes.
Recently, a retrospective study conducted in melanoma
samples found that significantly longer progression-free survival
and overall survival were observed in patients with pre-treatment
high IFN-γ expression (149). High pre-treatment expression
of IFN-γ-inducible genes (e.g., IDO1, CXCL9, CXCL10, and
CXCL11 among others) was associated with response and
prolonged overall survival for anti-PD-1 (pembrolizumab)
treatment of melanoma (149). In a cohort melanoma patients
treated with anti-CTLA-4 (ipilimumab; NCT00094653) Koguchi
et al. (137) found elevated pre-treatment serum levels of CXCL11
and a soluble MHC class I polypeptide-related chain (sMICA)
to be strong predictors of poor survival benefit, this finding
was confirmed in an independent cohort of melanoma patients
treated with ipilimumab (137). This finding is in contrast with
tumor tissue samples that favor CXCL11 as a biomarker of T
cell infiltration and therefore a favorable prognostic marker, as
mentioned above. CXCL11 also has distinct immunoregulatory
functions through the higher affinity to its receptor CXCR3
(125). CXCL11 is also capable of binding to CXCR7, more
commonly associated with tumor growth, making its functional
role controversial (125, 137, 149). In addition, the contrast in
findings between protein in the serum to mRNA levels in the
tissue microenvironment suggests that parallel analysis of both
serum and tissue, and protein and mRNA, maybe required
further clarify these differences (137).
Despite strong preclinical support of checkpoint inhibitor
for the treatment of non-melanoma skin cancers, little is still
known about blocking the PD-1/PD-L1 and CTLA-4 pathways
in patients. A number of single case studies have been published
on the use CPI in the treatment of these cancers, however due
to patient numbers investigation into biomarkers for predicting
treatment response has been limited. Chow et al. (150) were
the first to clinically assess the use of PD-1 and PD-L1 CPIs in
head and neck SCC. Keynote-012 stratified patients to assess the
response of PD-1 (pembrolizumab) on PD-L1-positive head and
neck SCC patients (150, 151). Using the identified gene signature
(CXCL9, CXCL10, IDO1, IFNG, HLA-DRA, and STAT1) that
was identified in the melanoma cohort and validated in a
head and neck SCC cohort (146, 147), all six of the IFN-γ -
related genes were statistically higher in responding patients
compared to non-responders. However, it should be noted
that the study only included PD-L1 positive patients. Further
work is needed to elucidate the interaction with PD-L1 and an
IFN-γ gene signature (151). Despite these initial findings, little
has been published regarding biomarker discovery, outside of
HPV status and PD-L1 expression (150, 160–163). Tumor tissue
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gene expression of similar IFN-γ gene signatures identified in
independent melanoma cohorts has also been correlated with
clinical benefit from anti-PD-1 treatment in a small number of
head and neck SCC patient cohorts (145, 148).
The use of CPI therapies for the treatment of BCC are
currently under clinical trial. A few promising case studies
have been published recently (73, 76, 164) with treated
efforts based predominately on the success of CPIs in similar
tumors with high mutational burdens, and from the finding
that ∼90% of BCCs stain positively for PD-L1 expression
(165). Recently, Lipson et al. (75) correlated the expression
of PD-L1 in the tumor microenvironment with predictability
for objective responses in PD-1-pathway-directed therapies
(75). It has also been established that BCCs undergoing
spontaneous regression (presumably immune-mediated) contain
elevated levels of Th1 cytokines (e.g., IFN-γ ) and infiltrating
activated T cells (166, 167). Additionally, treatments that
have focused on interferon therapy have shown efficacy in
BCC (168). MCC is a rare but aggressive skin cancer,
with several published studies finding expressed PD-L1 in
the tumor and also PD-1 expression on tumor-infiltrating
lymphocytes (159, 169–172). These observations provide a strong
rationale for assessing CPIs on patients with advanced disease
that has few therapies to extend survival. Current clinical
trial by Nghiem and colleagues treated patients with PD-1
(pembrolizumab), response to treatment did not correlate with
PD-L1 expression, so too in both virus negative and positive
cancers (172).
Although strongly biased by melanoma patient data, there
is strong evidence supporting the importance of an active
immune microenvironment for successful CPI therapy outcomes
in metastatic skin cancer. IFN-γ production by activated T
cells is capable of multitude of downstream affects, including
activation of dendritic cells and macrophages (like, STAT1 and
CMKLR1), which in turn produce their own chemokines and
cytokines (like, CCL5, CXCL9,-10,-11) to further recruit CD8T
cells. Upregulation of co-stimulatory molecules (CD27) and
effector molecules (IFN-γ , perforin, and granzymes) further
contribute to the immune response. IFN-γ induces upregulation
of HLA molecules and other pathway associated with antigen
processing and presenting. IFN-γ also drives upregulation of
PD-L1 and PD-L2 on the surface of macrophages, DCs and
tumor cells. Other checkpoint molecules like IDO1, TIGIT
and LAG3 are similarly associated with T cell activation
and IFN-γ signaling to help restrain antitumor responses
(145). The use of gene expression signature highlights the
complexity within the immune response associated with CPI
treatment and response and suggests the importance of multiple
cell types within the tumor microenvironment. These gene
expression profiles provide an interesting insight into the
immune responses to CPI therapy and highlight a number of
possible targets that can be manipulated for better therapeutic
outcomes.
IL-6 and IL-8
IL-6 is a pleiotropic cytokine that is associated similarly with
disease pathogenesis and metastasis and has already been
published as a serum marker for melanoma patients. IL-6 has
also been linked to IL-10 production within the melanoma tumor
microenvironment. For head and neck SCC, BCC, and mMCC
high IL-6 levels are also associated with a poor prognosis and
treatment resistance (173). The expression of PD-L1 has also
been linked to IL-6 and IL-10 cytokines, which may explain their
role in tumor progression and as a marker of non-response.
Bjoern et al. (136) found MM patient cohort following CTLA-
4 treatment (ipilimumab) who had lower serum baseline levels
and lower levels at the 4th dose of pro-inflammatory cytokine IL-
6 responded better to therapy (136). This observation of serum
IL-6 as a poor prognostic biomarker for MM immunotherapy
responses has been previously suggested in IL-2-based and bio-
chemotherapy therapies (174, 175). Pre-treatment serum levels
of IL-6, IFN-γ , and IL-10 were found to be significantly higher
in patients with objective tumor responses in a cohort of phase
2 advanced melanoma patients treated with PD-1 (nivolumab)
in comparison to non-responders with progressive disease (134).
The increased cytokine levels were also positively correlated
with each other, suggesting both a spontaneous activation and
suppressive response at the same time (134). In addition,
the group found increases in CXCL9 and CXCL10 between
pre-treatment and post-treatment (Day 43) serum samples in
response to treatment, postulated to be associated with IFN-γ
production by activated T cells in the blood (134).
IL-8 serum levels have been proposed to reflect tumor burden
and decreased levels in a small cohort of MM patients during
treatment with CTLA-4 (ipilimumab) correlated with patient
benefit from treatment (138). Sanmamed et al. found that serum
IL-8 levels are a consequence of tumor burden in a number of
cancer types including melanoma and could be monitored to
predict response to BRAF inhibitors and correlated to overall
survival (138). In addition, the authors recently published that
changes in serum IL-8 levels reflect tumor response to PD-1
treatment (nivolumab or pembrolizumab) in MM patients in
both identification cohort and independent validation cohort
(139). Decreases in IL-8 serum levels were found at patient’s
best response, additionally, they were able to distinguish pseudo-
progression (decreased) and non-responders (increased) and also
monitor responses via IL-8 serum fluxes (139). IL-8 has been
similarly implicated as a biomarker for head and neck SCC
patients receiving chemoradiation with or without novel hypoxic
cytotoxins (176). A recently published case report describing
a recurrent head and neck SCC patient on PD-1 (nivolumab)
treatment found increased levels of IL-8 and IL-6 following
treatment (from pre-treatment levels) and decreased levels of
IL-10 and CXC3C1, the patient was found to have progressive
disease (177), this cytokine and chemokine profile is constant
previously published work from a cohort of melanoma and non-
small-cell lung cancer patients (139). The role of IL-8 and its
receptor CXCR2 in tumor development and progression has
been well-documented in a wide range cancer cells including
melanoma, SCC, BCC, and MCC (18, 146, 178–182). IL-8, and
its receptor CXCR2, are poised to be examined as potential
biomarkers in both BCC and mMCC treated with CPIs. The
induction of pro-inflammatory cytokines like IL-6 and IL-
8, appear strong indicators of unsuccessful CPI therapy and
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highlight the need for biomarkers for patients who will not
respond to treatment as well as for those who will.
PREDICTIVE BIOMARKERS FOR
IMMUNE-RELATED ADVERSE EVENTS
As stated above, checkpoint inhibitor therapy can be associated
with severe or even life-threatening irAEs. Generally, irAEs
occur within weeks to 3 months after initiation of treatment but
have been documented to occur months after discontinuation
of treatment. Fatigue is the most common irAE reported
following treatment with either anti-CTLA-4 and anti-PD1/anti-
PDL-1 antibodies and can range up to 50% (183). For PD-1
based therapy, the next most common (10–20%) are grade 1-
2 skin rash, transaminitis, arthralgia, colitis, low-grade fevers,
thyroiditis, and other endocrinopathies. For CTLA-4 based
therapies, the next most common (20–30%) are grade 1–2
colitis, anemia, transaminitis, skin rash, arthralgia, and low-grade
fevers(184). Grade 3–4 irAEs are rare for PD-1 based therapies
but are more common in CTLA-4 based or combination
CTLA-4 plus PD-1 therapies, and are mostly commonly colitis,
transaminitis, and endocrinopathies. In addition, there are also
a number of rare (<1%) immune-related adverse events that
have also been reported following CPI treatment including
Type I Diabetes and systemic lupus erythematosus (50, 185,
186). The causes and mechanisms of these various irAEs are
an area of active investigation. We need to have predictive
biomarkers for therapy response to maximize benefit as well
as predictive biomarkers for irAEs to minimize risk, however,
biomarkers for irAEs have been less vigorously investigated
than biomarkers that predict therapy response. Nevertheless,
as more and more immunotherapy are being deployed, some
predictive immune signals are beginning to surface. For example,
increased overall white blood cell count and eosinophil count
with decreased relative lymphocyte count have been associated
with higher grade irAEs (187, 188). Increased T-cell repertoire
diversity is associated with more irAEs in patients treated with
ipilimumab (189, 190). A post combination anti-CTLA-4 and
anti-PD-1 therapy reduction in total peripheral B cells with an
enrichment of CD21lo PD-1+ memory B cells correlated with
irAE development (191). Increases in circulating autoantibodies
against self-antigens and mRNA gene expression signatures
of immune activation have been correlated with impending
irAEs (192–195). Finally, as mentioned, IL-17 levels may be
associated with gastrointestinal toxicities (135). As most studies
are small and not repeated in large-scale clinical trials, more
work is needed before effective predictors of irAEs are clinically
available.
NOVEL TECHNOLOGIES AND ASSAYS
UNDER INVESTIGATION
Biomarker assays that require the smallest amounts of accessible
samples, for instance, blood and other bodily fluids from
patient clinical samples, will inherently be less invasive and
more likely to be implemented in a clinical setting. Blood
biomarkers such as circulating tumor DNA may allow for
more meaningfully analysis of patients tumor response with
smaller blood volumes in comparison to approaches capturing
circulating tumor cells and have been recently reviewed (196,
197). These approaches have the potential to overcome the tumor
heterogeneity and sample quantity procurement limitations of
tumor biopsies. A number of biotech companies including
Grail, Freenome, and Guardant Health are utilizing this
approach to create assay platforms that improve early cancer
detection and immunotherapy responses for better outcomes. In
addition, recent advancements in imaging are allowing for non-
invasive evaluation of the tumor immune-microenvironment
and have been recently well-reviewed (198). Using PET scan
in conjunction with antibodies or antibody fragments labeled
with PET-based radionuclides, scanners have the potential to
detect T-cell subsets and effector molecules within tumors or
lymphoid tissues and non-invasively monitor changes within
the tumor microenvironment throughout the immunotherapy
treatment process. Technologies such as this may help clinicians
to better distinguish patients with true disease progression,
which requires the timely transition to alternative treatments,
from pseudoprogression, a phenomenon characterized by the
transient increase in tumor size followed by a decrease, where
immunotherapy should be continued.
DISCUSSION
Immunotherapies such as CPIs are demonstrating
unprecedented response rates across all major types of
metastatic skin cancers. Unlike traditional cancer treatment
modalities, the durability of response seen in CPIs enabled
clinician and patients alike to consider the possibility of cures
in a historically highly resistant and fatal group of cancers.
Building upon that success, efforts are underway to further
improve response rates and more precisely deliver treatment
to patients who are most likely to respond while monitoring
treatment outcomes in a timely fashion. These efforts will likely
serve to ameliorate the problem of high cost and unpredictability
of cancer immunotherapy. This review attempts to summarize
the tools currently available for clinical practice as well as
technologies in emerging areas of discovery. As combination
immunotherapy and associated biomarkers gain sophistication,
efforts to prioritize the tools available and to standardize
practice methods will require dedicated large studies. It is
established that immune impairment is common among cancer
patients, with the entity of metastatic skin cancer every so
close to finally achieving improved clinical outcomes for its
patients using immunotherapy, the mechanistic understanding
of the tumor microenvironment and lessons learned from
improving this field will hopefully benefit other disease entities
as well.
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